HLB develops the ‘Rivoceranib’, the Best-in-class
targeted therapy for unmet medical needs in cancer.
Leader of Global
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
Apealea completes Pre-NDA meeting
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th...
Immunomic Therapeutics, EPIVAX, Pha...
- Agreement of COVID-19 Vaccine Joint DevelopmentAccording to a foreign press reported at 5 o'clock in the morning, thre...
Replicate Bioscience and ITI Form C...
Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technolo...
Immunomic Therapeutics to Present a...
Immunomic Therapeutics, Inc. will present preclinical data on its investigational nucleic acid platform, UNITE (Univer...
Low-dose apatinib monothe...
AbstractThe therapeutic regimen for small cell lung cancer (SCLC)...
Tumor Angiogenesis and An...
AbstractAngiogenesis is the process through which novel blood ves...